Market Cap: $2.64B
VI
Viridian Therapeutics, Inc.
VRDN
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $2.64B
Viridian Therapeutics (Ticker: VRDN) significantly enhances its financial position by repaying a $55.1 million term loan to Hercules Capital. This strategic move, completed in late May 2026, eliminate…
Viridian Therapeutics (Ticker: VRDN) has successfully completed a significant financial maneuver by repaying approximately US$55.10 million of its Hercules term loan. This successful repayment marks a…
Viridian Therapeutics (Ticker: VRDN) has recently achieved a significant milestone with its announcement of positive topline results from the REVEAL-2 phase 3 clinical trial. This trial evaluates eleg…
Promising Advancements in Proptosis Treatment with Elegrobart Viridian Therapeutics is making significant strides in the treatment of proptosis, demonstrated by its recent REVEAL-1 trial involving the…
Promising Advances in Proptosis Treatment: Elegrobart's Efficacy Revealed in REVEAL-1 Trial The recent results from the REVEAL-1 trial mark a significant advancement in the treatment landscape for pro…
Viridian Therapeutics: Sustained Growth in Innovative Therapeutics Viridian Therapeutics showcases notable progress in its Q4 earnings report released on February 26, 2026. The report reveals that the…
Viridian Therapeutics: Driving Innovation in Therapeutics through Strategic Growth and Research Investments Viridian Therapeutics, a notable player in the biotechnology sector, delivers strong perform…
Viridian Therapeutics Demonstrates Strong Q4 Performance and Robust Growth Outlook Viridian Therapeutics showcases a promising quarter in its recently released Q4 earnings report, revealing significan…
Viridian Therapeutics: Pioneering Treatments for Rare Diseases Viridian Therapeutics Inc. is gaining attention in the biotechnology sector for its commitment to developing innovative therapies targeti…
Viridian Therapeutics Faces Analysts' Mixed Sentiments Amidst Development Phase Viridian Therapeutics, a player in the biopharmaceutical industry, draws attention from six analysts who provide a spect…
Viridian Therapeutics Advances Clinical Pipeline with Promising Results Viridian Therapeutics, Inc. (VRDN) showcases significant progress in its clinical and financial performance during the second qu…
Viridian Therapeutics Advances in Thyroid Eye Disease Treatment Viridian Therapeutics, Inc. (VRDN) makes significant strides in its clinical programs as it announces positive results for the second qu…
Viridian Therapeutics Advances in Ophthalmology with Promising Clinical Results Viridian Therapeutics, Inc. (VRDN) announces positive developments in its clinical and financial performance for the sec…
Viridian Therapeutics Advances Talent Acquisition with Inducement Grants Viridian Therapeutics, Inc., a biopharmaceutical company located in Waltham, Massachusetts, is actively enhancing its workforce…
Viridian Therapeutics Advances Innovative Treatments for Rare Diseases Viridian Therapeutics, Inc., a biopharmaceutical company based in Waltham, Massachusetts, is making significant strides in the de…
Viridian Therapeutics Advances Pivotal Trials for Thyroid Eye Disease Treatments Viridian Therapeutics, Inc., a biopharmaceutical firm located in Waltham, Massachusetts, is making significant strides…
Viridian Therapeutics Expands Talent Pool to Accelerate Drug Development Viridian Therapeutics, Inc., a biotechnology firm based in Waltham, Massachusetts, continues to bolster its workforce as it adv…